Tumor therapeutic agent, and complex

A tumor therapeutic agent using an acrolein-reactive complex to selectively release an S1P signaling inhibitor within tumors addresses the limitations of existing anticancer drugs by reducing immunosuppressive effects and enhancing cancer cell targeting, effectively treating multidrug-resistant tumors.

WO2024247648A1PCT designated stage expired Publication Date: 2024-12-05HYOGO MEDICAL UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017295
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-09
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current anticancer drugs targeting the S1P signaling pathway face challenges due to strong immunosuppressive effects on normal cells and limited therapeutic efficacy on cancer cells, with existing S1P receptor modulators and sphingosine kinase inhibitors exhibiting undesirable side effects and limited cancer treatment benefits.

Method used

A novel tumor therapeutic agent comprising a complex with an acrolein reactive site and a sphingosine-1-phosphate receptor modulator linked via a cleavable linker, which reacts with acrolein to release an S1P signaling inhibitor, reducing immunosuppressive effects on normal cells and enhancing cancer cell targeting.

Benefits of technology

The complex effectively inhibits tumor cell growth and metastasis while minimizing side effects on normal cells by selectively releasing the S1P signaling inhibitor within the tumor microenvironment, demonstrating potent antitumor activity against multidrug-resistant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017295_05122024_PF_FP_ABST
    Figure JP2024017295_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a novel drug for tumor therapy which targets an S1P signaling pathway. A tumor therapeutic agent according to one embodiment of the present invention which comprises a complex that includes an acrolein reaction site having a chemical structure represented by formula (1), and a detachment site, wherein the detachment site is bonded to the acrolein reaction site via a linker that can be cleaved by a reaction between the acrolein reaction site and acrolein, and the detachment site includes a chemical structure of a compound which exhibits an activity for inhibiting sphingosine-1-phosphate signal transduction in a cell.
Need to check novelty before this filing date? Find Prior Art

Description

Tumor therapeutic agents and conjugates

[0001] The present invention relates to tumor therapeutic agents and conjugates.

[0002] Sphingosine-1-phosphate (S1P) is known to be involved in angiogenesis, lymphangiogenesis, etc. by binding to S1P receptors expressed on endothelial cells. In addition, it has been reported that the S1P signaling pathway is involved in tumor cell proliferation, migration, survival, etc. (Non-Patent Documents 1 to 7).

[0003] Fingolimod (also known as "FTY720"), an S1P receptor modulator, inhibits the S1P signaling pathway by suppressing S1P receptors and S1P-producing enzymes. FTY720 is covered by health insurance in Japan as a treatment for multiple sclerosis. Furthermore, in vitro experiments have shown that FTY720 effectively suppresses cancer growth and metastasis (Non-Patent Document 8).

[0004] However, the development of anticancer drugs targeting the S1P signaling pathway has not progressed for the following reasons: First, S1P receptor modulators such as FTY720 exert strong immunosuppressive effects in vivo, which poses a problem of side effects on normal cells. Furthermore, from the perspective of cancer treatment, the immunosuppressive effects of S1P receptor modulators contradict one of the methodologies of cancer treatment, which is to abrogate antitumor immunity against cancer cells.

[0005] Attempts have also been made to develop anticancer drugs that target sphingosine kinase, which is located further upstream in the S1P signaling pathway. However, it has been reported that sphingosine kinase inhibitors are not expected to have a therapeutic effect on cancer cells (Non-Patent Document 9).

[0006] Incidentally, Patent Document 1 describes a complex that reacts with acrolein to release an active substance, and a tumor therapeutic agent containing the complex.

[0007] Acrolein (CH 2=CHCHO) is the smallest unsaturated aldehyde molecule and is a highly reactive molecule. Acrolein is known to be generated during the combustion of organic matter, and is also thought to be generated in vivo as a metabolic product of lipids or polyamines in diseases associated with oxidative stress, such as cancer, Alzheimer's disease, and cerebral infarction. It has been reported that tumor cells generate more acrolein than normal cells, with the amount being more than 1,000 times that of normal cells at the site of inflammation (Non-Patent Documents 10-12).

[0008] Patent Document 1 describes that by incorporating an existing antitumor compound into a conjugate to make it in a prodrug state, the antitumor activity (toxicity) of the compound can be attenuated, and that the conjugate can react with acrolein present around tumor cells to release the antitumor compound. Thus, the technology of Patent Document 1 makes it possible to control the antitumor activity of an existing antitumor compound established as an anticancer agent so that it is exerted around tumor cells.

[0009] International Publication No. 2022 / 085523

[0010] Nagahashi M et al., Biomed Research International 2014;2014: 651727Takabe K and Nagahashi M, et al. J Biol Chem 2010;285:10477-10486Nagahashi M, et al. Cancer Res 2012;72:726-735; Nagahashi M, et al. FASEB J 2013;27:1001-1011Liang J and Nagahashi M, et al. Cancer Cell 2013;23:107-120Nagahashi M, et al. Hepatology 2015;61:1216-1226Nagahashi M, et al. Cancer Res 2018Tsuchida J and Nagahashi M, et al. J Surg Res 2021Chiba K et al. Inflammation and Regeneration 2011;31:167-174Schnute ME, et al. Biochem J 2012 444:79-88Tanaka, K. et al. Adv. Sci. 2019, 6, 1801479Tanaka, K. et al. Bioorg. Med. Chem. 2019, 27, 2228Tanaka, K. et al. Adv. Sci. 2020, 1901519

[0011] There is a need for the development of novel therapeutic agents for tumors that target the S1P signaling pathway. However, Patent Document 1 only describes conjugates with existing antitumor compounds (existing anticancer drugs).

[0012] One aspect of the present invention aims to provide a novel agent for tumor treatment that targets the S1P signaling pathway.

[0013] In order to solve the above-mentioned problems, the present invention includes the following aspects: A tumor therapeutic agent comprising a complex including an acrolein reactive site and a release site, the complex having a chemical structure represented by formula (1), wherein the release site is bound to the acrolein reactive site via a linker that is cleavable upon reaction between the acrolein reactive site and acrolein, and the release site includes the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with a linker.)

[0014] The present invention also includes the following aspects: A therapeutic agent for multidrug-resistant tumors, which comprises as an active ingredient a compound having activity of inhibiting sphingosine-1-phosphate signal transduction in cells.

[0015] The present invention also includes the following aspects: A conjugate comprising an acrolein reactive site and a release site, each having a chemical structure represented by formula (1), wherein the release site is bonded to the acrolein reactive site via a linker that is cleavable by a reaction between the acrolein reactive site and acrolein, and the release site comprises the chemical structure of a sphingosine-1-phosphate receptor modulator. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with a linker.)

[0016] According to one aspect of the present invention, a novel agent for tumor treatment that targets the S1P signaling pathway can be provided.

[0017] 1 is a diagram showing the results of comparing the growth inhibitory effect of each drug in Comparative Examples 1 to 3 and Example 1 on normal breast cancer strains and multidrug-resistant breast cancer strains. 2 is a diagram showing the results of comparing the growth inhibitory effect of each drug in Examples 2 to 5 on normal breast cancer strains and multidrug-resistant breast cancer strains. 3 is a diagram showing the results of comparing tumor weight, percentage of lymphocytes in blood samples, and lymphocyte count. 4 is a diagram showing the results of comparing the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in plasma. 5 is a diagram showing the results of comparing the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in tissues. 6 is a diagram showing the results of comparing the growth inhibitory effect of each drug in Comparative Examples 1 to 3 and Example 2 on organoids derived from breast cancer patients.

[0018] Hereinafter, one embodiment of the present invention will be described in detail. In this specification, unless otherwise specified, the expression "A to B" representing a range of numerical values ​​means "A or more and B or less."

[0019] <1. Tumor Therapeutic Agent> A tumor therapeutic agent according to one embodiment of the present invention (hereinafter also referred to as "first tumor therapeutic agent") comprises a complex having a chemical structure represented by formula (1) and including an acrolein reactive site and a release site, wherein the release site is bound to the acrolein reactive site via a linker that is cleavable by the reaction of the acrolein reactive site with acrolein, and the release site comprises the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells.

[0020] As used herein, "treatment" includes causing tumor cells in tumor tissue to regress or decrease compared to before administration of a tumor therapeutic agent according to one embodiment of the present invention (hereinafter simply referred to as "administered subject"), eliminating (eliminating) tumor cells in tumor tissue, or preventing tumor progression in a subject to whom the tumor therapeutic agent according to one embodiment of the present invention has been administered.

[0021] [Conjugate] The conjugate (hereinafter also simply referred to as "the conjugate") contained in the tumor therapeutic agent according to one embodiment of the present invention includes an acrolein reactive site and a detachable site having a chemical structure represented by formula (1), and the detachable site is bonded to the acrolein reactive site via a linker that is cleavable by the reaction of the acrolein reactive site with acrolein.

[0022] This complex contains acrolein (2-propenal, CH 2 In the presence of acrolein, the linker is cleaved and the release site is released in the presence of the azide group (N = CHCHO) in the acrolein-reactive site of this conjugate. 3 This is because the 1,3-dipole group undergoes a 1,3-dipole cycloaddition reaction (click reaction) with acrolein, a dipolarophile, to produce a five-membered ring (1,2,3-triazoline) intermediate.

[0023] The 1,2,3-triazoline produced by the click reaction (1,3-dipolar cycloaddition reaction) between the acrolein reactive site and acrolein then undergoes an isomerization reaction to form an imine, and with subsequent decarboxylation (release of carbon dioxide), the linker between the acrolein reactive site and the release site is cleaved, resulting in separation into a diazo compound derived from the acrolein reactive site and an active substance derived from the release site.

[0024] The above reaction can proceed under mild conditions, such as in vivo, and exhibits high reaction specificity. Therefore, by administering the present complex to a living body, endogenous acrolein reacts with the complex, resulting in the release of the active substance derived from the release site into the living body.

[0025] (Regarding R1 and R2) In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms.

[0026] Examples of halogen atoms include fluorine atoms, chlorine atoms, and bromine atoms. The fluorine atoms may be isotopes.

[0027] The alkyl group having 1 to 5 carbon atoms may be either linear or branched. The hydrogen atom of the alkyl group may be substituted with at least one of the above-mentioned halogen atoms, or may be unsubstituted. Examples of alkyl groups having 1 to 5 carbon atoms and no hydrogen atom substituted include a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a tert-pentyl group, and a sec-pentyl group.

[0028] R1 and R2 may be the same or different, but from the viewpoint of improving the reactivity with acrolein, it is preferable that both R1 and R2 are alkyl groups having 1 to 5 carbon atoms which may or may not be substituted with at least one halogen atom, and it may be more preferable that they are the same alkyl group. Note that the number of carbon atoms constituting the alkyl group may be preferably 1 to 4, and may be more preferably 2, 3, or 4.

[0029] In another embodiment, it may be preferred that one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms, which may or may not be substituted with at least one halogen atom, and the other of R1 and R2 is a halogen atom (particularly, fluorine or an isotope). The number of carbon atoms constituting the alkyl group may preferably be 1 to 4, and more preferably 2, 3, or 4.

[0030] (Regarding R3 and R4) In formula (1), R3 and R4 are each independently a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms, provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent.

[0031] The definition and examples of halogen atoms are the same as those described for R1 and R2.

[0032] Examples of amino groups which may have a substituent include unsubstituted amino groups, alkylamino groups, and (hetero)arylamino groups. The number of carbon atoms constituting each alkyl group contained in the alkylamino group is, for example, 1 to 5. A (hetero)arylamino group refers to a group in which at least one hydrogen atom constituting the amino group is substituted with an aryl group (i.e., an aryl group or a heteroaryl group) which may have a heteroatom. Each (hetero)aryl group contained in the (hetero)arylamino group may, for example, have a ring structure skeleton formed by 3 to 20 (preferably 4 to 12) atoms. Note that examples of heteroatoms contained in the heteroaryl group include a sulfur atom, a nitrogen atom, and an oxygen atom.

[0033] Examples of the alkoxy group having 1 to 5 carbon atoms include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, and a butoxy group.

[0034] Examples of the alkylthio group having 1 to 5 carbon atoms include a methylthio group, an ethylthio group, a propylthio group, a butylthio group, and a pentylthio group.

[0035] The definition and examples of alkyl groups having 1 to 5 carbon atoms and in which hydrogen atoms are not substituted are the same as those described for R1 and R2. The number of carbon atoms constituting the alkyl group may preferably be 1 to 4, and more preferably 1 to 3. However, at least one of the hydrogen atoms constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent. Examples of the halogen atom and the amino group which may have a substituent include the same as those described for R3 and R4.

[0036] R3 and R4 may be the same or different, but it may be preferred that R3 and R4 are the same.

[0037] It is sometimes preferred that R3 and R4 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom. The definition and examples of the alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom are the same as those described for R1 and R2.

[0038] (Examples of preferred combinations of R1, R2, R3, and R4 located on the same ring) Example combination <1>: In formula (1), R1, R2, R3, and R4 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms. Example combination <2>: In formula (1), R3 and R4 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that R1 and R2 are alkyl groups having 1 to 5 carbon atoms. - Example combination <3>: In formula (1), R3 and R4 are each independently a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, and one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms, and the other of R1 and R2 is a halogen atom. - Example combination <4>: In the above example combination <1> or <2>, R3 and R4 are each independently a hydrogen atom or a halogen atom, and R1 and R2 are an alkyl group having 1 to 5 carbon atoms. - Example combination <5>: In the above example combination <3>, R3 and R4 are each independently a hydrogen atom or a halogen atom.

[0039] (Regarding *) In formula (1), * is, as described above, a binding site for a linker that links the release site. This linker can be cleaved by a reaction between the acrolein reactive site and acrolein. More specifically, this linker has a structure in which cleavage is promoted by a 1,3-dipolar cycloaddition reaction between the acrolein reactive site and acrolein to generate a five-membered ring.

[0040] (Linker) An example of a linker that can be cleaved by the reaction of the acrolein reactive site with acrolein is a linker having a chemical structure represented by formula (2).

[0041] (Regarding R) In formula (2), R are each independently a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms, provided that a hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent.

[0042] The definition and examples of halogen atoms are the same as those described for R1 and R2.

[0043] The definition and examples of the amino group which may have a substituent are the same as those described for R3 and R4.

[0044] Examples of the alkoxy group having 1 to 5 carbon atoms include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, and a butoxy group.

[0045] Examples of the alkylthio group having 1 to 5 carbon atoms include a methylthio group, an ethylthio group, a propylthio group, a butylthio group, and a pentylthio group.

[0046] The definition and examples of alkyl groups having 1 to 5 carbon atoms in which hydrogen atoms are not substituted are the same as those described for R1 and R2. The number of carbon atoms constituting the alkyl group may preferably be 1 to 4, and more preferably 1 to 3. However, at least one of the hydrogen atoms constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent. Examples of the halogen atom and the amino group which may have a substituent include the same as those described for R3 and R4.

[0047] R's bonded to the same carbon atom may be the same or different, but it is sometimes preferable that the R's are the same.

[0048] R may preferably be each independently a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms (wherein the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent), and may more preferably be each independently a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom. The definition and examples of the alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom are the same as those described for R1 and R2.

[0049] (Regarding * and **) In formula (2), ** is a bonding site with the release site. From the viewpoint of rapid cleavage of the linker, ** may preferably be a bonding site with a nitrogen atom, sulfur atom, or oxygen atom contained in the release site (i.e., -N(-)-, -S-, or -O-), and may more preferably be a bonding site with a nitrogen atom contained in the release site.

[0050] In formula (2), * denotes the binding site with the acrolein reactive site. Therefore, this complex having a linker with the chemical structure represented by formula (2) has a chemical structure represented by formula (3) below.

[0051] In formula (3), the definitions and examples of R1, R2, R3, R4, and R are the same as those described in the explanation of formula (1) and formula (2). In formula (3), ** is the same as that described in the explanation of formula (2).

[0052] A specific example of the complex having the chemical structure represented by formula (3) above is a complex (removal site-ABC) of the release site and 4-azidobenzylcarbamate (hereinafter also simply referred to as "ABC") represented by formula (4) below. In formula (4), ** is the bonding site to the nitrogen atom contained in the cleavage site. When ** is the bonding site to the nitrogen atom contained in the cleavage site, the chemical structures shown in formulas (3) and (4) above can also be considered as a protecting group for the amino group contained in the cleavage site that can be deprotected by acrolein.

[0053] (Reaction mechanism of linker cleavage) As an example of a conjugate according to one embodiment of the present invention, a conjugate in which a linker is bound to a nitrogen atom contained in the release site will be described below. The reaction mechanism by which a linker having a chemical structure represented by formula (2) is cleaved to release the release site (active substance) will be described below.

[0054] When this complex approaches acrolein, the azide group of this complex and acrolein undergo a 1,3-dipolar cycloaddition reaction to generate 1,2,3-triazoline as an intermediate. The five-membered ring (triazole ring) of 1,2,3-triazoline opens to generate a diazo compound, and intramolecular electron transfer begins. This causes cleavage between the carbonyl carbon in the linker and the nitrogen atom in the release site, releasing the release site as an active substance.

[0055] (Release Site) The release site of the present complex comprises the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells (hereinafter also referred to as "S1P signaling inhibitory compound"). "The release site comprises the chemical structure of the S1P signaling inhibitory compound" means that at least a part of the chemical structure of the release site contains the chemical structure of the S1P signaling inhibitory compound.

[0056] As described above, sphingosine-1-phosphate (S1P) is known to be involved in angiogenesis, lymphangiogenesis, etc. by binding to S1P receptors expressed on endothelial cells. In addition, in tumor cells, sphingosine-1-phosphate (S1P) is known to be involved in tumor cell proliferation, migration, survival, etc. (Non-Patent Documents 1 to 7).

[0057] Furthermore, the present inventors have discovered that tumor cells produce more acrolein than normal cells, with the amount being more than 1,000 times that of normal cells at inflamed sites (Non-Patent Documents 10 to 12). Therefore, the present conjugate having an S1P signaling inhibitory compound as a release moiety can react with acrolein present around tumor cells to release the S1P signaling inhibitory compound, and can therefore be suitably used as a tumor therapeutic agent.

[0058] The S1P signaling inhibitory compound used as the release site can be any compound that has activity of inhibiting sphingosine-1-phosphate signaling in cells, including S1P signaling inhibitory compounds that are being used in clinical or clinical trials and S1P signaling inhibitory compounds that will be developed in the future, without any limitations.

[0059] The S1P signaling inhibitor compound is preferably a compound having a nitrogen atom, a sulfur atom, or an oxygen atom as a binding site with the linker so that it can be rapidly cleaved from the linker. Furthermore, it may be preferable for the compound to have a hydroxyl group, a carboxyl group, a thiol group, or an amino group to facilitate binding with the linker. These functional groups may be functional groups that the S1P signaling inhibitor compound originally has, or may be functional groups that are added later to serve as binding sites with the linker.

[0060] The bond between the S1P signaling inhibitor compound and the linker is preferably one that can be rapidly cleaved by the reaction of the acrolein reactive site with acrolein. From this viewpoint, the bond between the cleavage site and the linker is preferably a carbamate bond, a thiocarbamate bond, an ester bond, or a thioester bond.

[0061] The S1P signaling inhibitor compound is preferably a hydrophobic compound from the viewpoint of ease of uptake into tumor cells.

[0062] The molecular weight of the S1P signaling inhibitor compound is not particularly limited, but is preferably low enough to reach tumor cells, for example, 15,000 Da or less, preferably 10,000 Da or less, more preferably 500 Da or less. The lower limit of the molecular weight of the S1P signaling inhibitor compound is not particularly limited, but is, for example, 100 Da or more, preferably 300 Da or more.

[0063] The S1P signaling inhibitor compound preferably has reduced S1P signaling inhibitory activity (toxicity) when bound to the acrolein reactive site via a linker, compared to when not bound, i.e., is in a prodrug state. The S1P signaling inhibitor compound exerts an immunosuppressive effect by inhibiting S1P signaling. By attenuating the immunosuppressive effect on normal cells, it is possible to reduce the impact on normal tissues and alleviate side effects.

[0064] The type of S1P signaling inhibitor is not particularly limited. For example, sphingosine-1-phosphate receptor modulators, S1P-producing enzyme inhibitors, etc. can be suitably used. Among them, from the viewpoint of the effect of inhibiting cancer cell proliferation, the S1P signaling inhibitor is preferably a sphingosine-1-phosphate receptor modulator.

[0065] Examples of S1P receptor modulators suitable for use as a release site include, but are not limited to, fingolimod (also referred to as "FTY720"), siponimod, ozanimod, and ponesimod. Among these, from the viewpoint of the cancer cell proliferation inhibitory effect, the S1P receptor modulator is preferably fingolimod, siponimod, ozanimod, or ponesimod. Furthermore, examples of S1P synthesizing enzyme inhibitors suitable for use as a release site include, but are not limited to, SK1-I ((2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol.HCl, also referred to as "BML258"). From the viewpoint of the cancer cell proliferation inhibitory effect, the S1P synthesizing enzyme inhibitor is preferably SK1-I.

[0066] A specific example of the complex having FTY720 as the release site is FTY720-ABC, which has the following chemical structure:

[0067] A specific example of the present conjugate having siponimod as the release moiety is siponimod-ABC, which has the following chemical structure:

[0068] Siponimod-ABC is an analog of siponimod in which 2-ethanolamine is added as an additional linker to the carboxyl group of siponimod, taking into consideration stability during retention in blood. In this way, a compound in which a linker is added to an S1P signaling inhibitor compound may be used as the release site.

[0069] The reaction mechanism by which siponimod (active substance) is released from siponimod-ABC is explained below.

[0070] Siponimod-ABC does not directly become "siponimod" through fragmentation after reacting with acrolein, but rather passes through "siponimod-2-ethanolamide" and is then rapidly converted by amidase in the blood into the active form, siponimod.

[0071] A specific example of this conjugate having ozanimod as the release moiety is ozanimod-ABC, which has the following chemical structure:

[0072] A specific example of the present conjugate having ponesimod as the release moiety is ponesimod-ABC, which has the following chemical structure:

[0073] [Method for Producing the Conjugate] The method for producing the conjugate will be described below using an example of the conjugate in which a linker having a chemical structure represented by formula (2) is bonded to the nitrogen atom at the release site (i.e., forming a carbamate bond).

[0074] The conjugates can be prepared by any method for synthesizing carbamate bonds, such as by reacting an isocyanate with an alcohol or an amine with a carbonate.

[0075] As a method for reacting an isocyanate with an alcohol, for example, an isocyanate can be obtained by reacting the amino group of a compound used as a leaving site with triphosgene in the presence of a suitable solvent, and then the obtained isocyanate can be reacted with an alcohol represented by formula (5) to produce the present complex having a carbamate bond.

[0076] As a method for reacting an amine with a carbonate ester, for example, an alcohol represented by formula (5) is reacted with a chloroformate ester in the presence of a suitable solvent to obtain a carbonate ester, and then the obtained carbonate ester is reacted with the amino group of a compound used as a leaving site, thereby producing the present complex having a carbamate bond formed.

[0077] For the method of producing this conjugate, see the description in the Examples and the description in ACS Sens. 2016, 1, 623-632 (Non-Patent Document 5). For example, the method of producing FTY720-ABC, whose chemical structural formula is shown above, is as shown in the Examples. Furthermore, since ozanimod has a secondary amine, ozanimod-ABC, whose chemical structural formula is shown above, can be produced by the same method as FTY720-ABC. Furthermore, since ponesimod has a hydroxy group, ponesimod-ABC, whose chemical structural formula is shown above, can be produced by the same method as FTY720-ABC.

[0078] A method for producing siponimod-ABC (hereinafter referred to as "BAF312-ABC"), the chemical structural formula of which is shown above, is described below.

[0079] As described above, BAF312-ABC, whose chemical structural formula is shown above, is an analog of siponimod in which 2-ethanolamine is added as an additional linker to the carboxyl group of siponimod. In producing BAF312-ABC, 2-ethanolamine is first added to siponimod (BAF312) to synthesize siponimod-2-ethanolamide, and then (4-azido-3,5-diisopropylphenyl)-methanol is added to the siponimod-2-ethanolamide to obtain BAF312-ABC.

[0080] (Other Components) The first tumor therapeutic agent may contain, in addition to the present conjugate, a pharmaceutically acceptable carrier, such as water, an electrolyte solution, or a sugar solution, as long as the carrier does not inhibit the activity of the present conjugate.

[0081] The first tumor therapeutic agent may contain auxiliary agents, such as buffering agents, soothing agents, stabilizers, preservatives, antioxidants, coloring agents, etc.

[0082] Examples of buffering agents include buffer solutions such as phosphate, acetate, carbonate, and citrate. Examples of soothing agents include propylene glycol, lidocaine hydrochloride, benzyl alcohol, benzalkonium chloride, and procaine hydrochloride. Examples of stabilizers include human serum albumin and polyethylene glycol. Examples of preservatives include benzyl alcohol and phenol. Examples of antioxidants include sulfites and ascorbates. Suitable examples of coloring agents include water-soluble colored tar dyes (e.g., food dyes such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5, and Food Blue No. 1 and No. 2), insoluble lake dyes (e.g., aluminum salts of the above-mentioned water-soluble food tar dyes), and natural dyes (e.g., β-carotene, chlorophyll, and red iron oxide).

[0083] The first tumor therapeutic agent may contain additives such as binders, excipients, lubricants, sweeteners, flavoring agents, preservatives, disintegrants, suspending agents, solvents, solubilizers, isotonicity agents, and swelling agents.

[0084] Examples of binders include gelatin, corn starch, tragacanth, gum arabic, pregelatinized starch, sucrose, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

[0085] Examples of excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethylcellulose, gum arabic, pullulan, soft anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate, xylitol, sorbitol, and erythritol.

[0086] Lubricants include magnesium stearate, calcium stearate, talc, colloidal silica, polyethylene glycol, and the like.

[0087] Examples of sweeteners include sodium saccharin, dipotassium glycyrrhizinate, aspartame, and stevia.

[0088] Flavoring agents include peppermint, rhododendron oil, cherry, and the like.

[0089] Examples of preservatives include parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid.

[0090] Examples of disintegrants include lactose, sucrose, starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethylstarch sodium, low-substituted hydroxypropylcellulose, soft anhydrous silicic acid, calcium carbonate, and the like.

[0091] Examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; polysorbates, and polyoxyethylene hydrogenated castor oil.

[0092] Suitable examples of the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil, and the like.

[0093] Suitable examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, and sodium acetate.

[0094] Suitable examples of the isotonic agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, xylitol, fructose, and the like.

[0095] (Dosage Form) The first tumor therapeutic agent can be administered as an oral preparation, an injection, or a transdermal preparation. Oral preparations include tablets (including sublingual tablets and orally disintegrating tablets), capsules (including soft capsules and microcapsules), powders, granules, lozenges, syrups, emulsions, suspensions, etc. Injections include intradermal injections, subcutaneous injections, intravenous injections, intramuscular injections, intraspinal injections, epidural injections, local injections, etc. Transdermal preparations include patches, ointments, dusting powders, etc. These preparations may be controlled-release preparations such as immediate-release preparations or sustained-release preparations (e.g., sustained-release microcapsules).

[0096] (Manufacturing Method) The first tumor therapeutic agent is preferably formulated as an injection. Sterile compositions for injections can be formulated according to conventional pharmaceutical practices, such as dissolving or suspending an active substance in a vehicle (aqueous solution for injection; naturally occurring vegetable oils such as sesame oil and coconut oil). Examples of aqueous solutions for injection include physiological saline, isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.), and the like, which may be used in combination with appropriate solubilizers such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants (e.g., polysorbate 80™, HCO-50), etc. Examples of oily solutions include sesame oil and soybean oil, which may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol. Injections can be packaged in unit doses or multiple doses in containers such as ampoules or vials. Alternatively, the active ingredient and a pharmaceutically acceptable carrier can be freeze-dried and stored in a state in which it is sufficient to dissolve or suspend them in an appropriate sterile vehicle immediately before use.

[0097] (Content of the present complex) The content of the present complex in the first tumor therapeutic agent varies depending on the form of the formulation, but is usually about 10 to 25% by mass, preferably about 15% by mass or more, and more preferably about 20% by mass or more, of the total formulation.

[0098] (Dosage) The dosage of the first tumor therapeutic agent can be determined appropriately taking into consideration the type of subject, the administration method, the type of S1P signaling inhibitor compound, the type and site of tumor cells, and the like. An appropriate dosage for humans can be determined from the results of animal experiments. For example, when FTY720-ABC is administered intravenously to solid tumors, experiments using mice have shown that the dosage is preferably 0.1 to 5 mg, more preferably 0.3 mg or more, and even more preferably 1 mg or more, of FTY720 per kg of body weight. When this is converted to a human equivalent dose using known methods, an appropriate dosage for humans based on the human equivalent dose is preferably 0.008 to 0.4 mg, more preferably 0.024 mg or more, and even more preferably 0.08 mg or more, of FTY720 per kg of body weight. These effective amounts can be administered once or in divided doses.

[0099] (Subject of Administration) The first tumor therapeutic agent can be applied to tumors in any mammal. The type of mammal may be a non-human mammal or a human. Examples of non-human mammals include rodents such as mice, rats, hamsters, and guinea pigs, laboratory animals such as rabbits, livestock such as pigs, cows, goats, horses, sheep, and mink, pets such as dogs and cats, and non-human primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees.

[0100] The subject to which the first tumor therapeutic agent is administered is a subject having a tumor. The type of tumor is not particularly limited, and examples thereof include lung cancer (e.g., lung adenocarcinoma), uterine cancer (e.g., cervical cancer, endometrial cancer), gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, gallbladder / bile duct cancer, breast cancer, bladder tumor, osteosarcoma, malignant melanoma, and pheochromocytoma.

[0101] The first tumor therapeutic agent is also effective against multidrug-resistant tumors. Therefore, the tumor therapeutic agent according to one embodiment of the present invention may be a therapeutic agent for multidrug-resistant tumors. The subject to which the multidrug-resistant tumor therapeutic agent according to one embodiment of the present invention is administered is the subject having a multidrug-resistant tumor. Here, in this specification, "multidrug-resistant tumor" means a tumor that is resistant to at least two types of chemotherapeutic agents. Resistance to a chemotherapeutic agent means that the effect of the chemotherapeutic agent is lower than that of a tumor of the same type that is sensitive to the chemotherapeutic agent, for example, means that the growth inhibitory effect of the chemotherapeutic agent is lower than that of a tumor of the same type that is sensitive to the chemotherapeutic agent. The at least two types of chemotherapeutic agents may be chemotherapeutic agents having different chemical structures or different mechanisms of action against tumors. The chemotherapeutic agents are, for example, anticancer drugs. The mechanism of resistance acquisition in multidrug-resistant tumors is not particularly limited.

[0102] The type of multidrug-resistant tumor is not particularly limited, but examples include multidrug-resistant tumors of all types of tumors, such as lung cancer (e.g., lung adenocarcinoma), uterine cancer (e.g., cervical cancer, endometrial cancer), gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, gallbladder / bile duct cancer, breast cancer, bladder tumor, osteosarcoma, malignant melanoma, and pheochromocytoma.

[0103] An example of a multidrug-resistant tumor is breast cancer that is resistant to at least two anticancer drugs selected from the group consisting of eribulin, doxorubicin, and paclitaxel. As shown in the Examples below, this conjugate has an S1P signaling inhibitor compound as a release site, and is therefore effective against the multidrug-resistant breast cancer.

[0104] (Effects) The first tumor therapeutic agent includes a complex having an S1P signaling inhibitory compound as a release moiety. Because the first tumor therapeutic agent contains the S1P signaling inhibitory compound as an active ingredient, it is expected to be effective in treating tumors in patients when administered to a patient with a tumor. The first tumor therapeutic agent is expected to be effective in treating multidrug-resistant tumors that cannot be treated with conventional anticancer drugs.

[0105] Furthermore, a complex having an S1P signaling inhibitory compound as a release site can react with acrolein present around tumor cells to release the S1P signaling inhibitory compound, and therefore can be suitably used as a therapeutic agent for tumors.

[0106] 2. Therapeutic Agent for Multidrug-Resistant Tumors A therapeutic agent for multidrug-resistant tumors according to one embodiment of the present invention (hereinafter also referred to as the "second tumor therapeutic agent") contains an S1P signaling inhibitory compound as an active ingredient. The S1P signaling inhibitory compound, which is the active ingredient of the second tumor therapeutic agent, may or may not be incorporated into the above-described conjugate as a release site. The conjugate having an S1P signaling inhibitory compound as a release site has already been explained in the above section "1. Therapeutic Agent for Tumors," and therefore will not be explained again here. Furthermore, an S1P signaling inhibitory compound not incorporated into the conjugate is similar to the S1P signaling inhibitory compound incorporated into the conjugate as a release site, except that it is not incorporated into the conjugate. Furthermore, the S1P signaling inhibitory compound, which is the active ingredient of the second tumor therapeutic agent, may be made into a prodrug by a method different from that of the above-described conjugate. That is, it may be made into a prodrug by adding a probe having a chemical structure represented by formula (1) other than an acrolein-reactive site to the S1P signaling inhibitory compound.

[0107] The second tumor therapeutic agent is a therapeutic agent for multidrug-resistant tumors. Multidrug-resistant tumors have already been described above in the section "1. Tumor therapeutic agents," and therefore, the description will not be repeated here. Other ingredients contained in the second tumor therapeutic agent, the dosage form of the second tumor therapeutic agent, the manufacturing method, the content of the S1P signaling inhibitor compound in the second tumor therapeutic agent, the dosage, and the administration target are the same as those for the first tumor therapeutic agent, and therefore, the description will be omitted.

[0108] (Effect) The second tumor therapeutic agent contains an S1P signaling inhibitor compound as an active ingredient, and therefore, when administered to patients with multidrug-resistant tumors, it is expected to be effective in treating multidrug-resistant tumors that cannot be treated with conventional anticancer drugs.

[0109] 3. Summary of Embodiments Embodiments of the present invention include, for example, the following aspects: [1] A tumor therapeutic agent comprising a complex including an acrolein reactive site and a release site, the complex having a chemical structure represented by formula (1), wherein the release site is bonded to the acrolein reactive site via a linker that is cleavable upon reaction between the acrolein reactive site and acrolein, and the release site includes the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that a hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * indicates a bonding site with the linker.) [2] The tumor therapeutic agent according to [1], wherein the linker has a chemical structure represented by formula (2). (In formula (2), R's each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (with the proviso that a hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with the acrolein reaction site, and ** represents a bonding site with the detachment site.) [3] The tumor therapeutic agent according to [2], wherein the ** in formula (2) represents a bonding site with a nitrogen atom, a sulfur atom, or an oxygen atom contained in the detachment site. [4] The tumor therapeutic agent according to [2], wherein R's each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms (with the proviso that a hydrogen atom constituting the alkyl group may have a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent). [5] The tumor therapeutic agent according to any one of [1] to [4], wherein R1 and R2 in formula (1) each independently represent an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom. [6] The tumor therapeutic agent according to any one of [1] to [5], wherein the conjugate reacts with acrolein present around tumor cells to release the detachment site. [7] The tumor therapeutic agent according to any one of [1] to [6], wherein the compound having activity of inhibiting sphingosine-1-phosphate signal transduction in the cells is a sphingosine-1-phosphate receptor modulator. [8] The tumor therapeutic agent according to [7], wherein the sphingosine-1-phosphate receptor modulator is fingolimod, siponimod, ozanimod, or ponesimod. [9] The tumor therapeutic agent according to any one of [1] to [8], wherein the tumor is a multidrug-resistant tumor.

[10] The tumor therapeutic agent according to [9], wherein the multidrug-resistant tumor is a breast cancer that is resistant to at least two anticancer drugs selected from the group consisting of eribulin, doxorubicin, and paclitaxel. [1 ... therapeutic agent comprises, as an active ingredient, a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells.

[12] A complex comprising an acrolein reactive site and a release site, each having a chemical structure represented by formula (1), wherein the release site is bonded to the acrolein reactive site via a linker that is cleavable by a reaction between the acrolein reactive site and acrolein, and the release site comprises the chemical structure of a sphingosine-1-phosphate receptor modulator. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group of 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group of 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may be substituted, an alkoxy group of 1 to 5 carbon atoms, an alkylthio group of 1 to 5 carbon atoms, or an alkyl group of 1 to 5 carbon atoms (provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may be substituted); * indicates a bonding site to the linker.)

[13] The conjugate according to

[12] , wherein the sphingosine-1-phosphate receptor modulator is fingolimod, siponimod, ozanimod, or ponesimod.

[0110] 4. Pharmaceutical Product for Tumor Treatment Pharmaceutical products for tumor treatment comprising the above-described first or second tumor therapeutic agent are also included in the scope of the present invention. The first or second tumor therapeutic agent in the pharmaceutical product for tumor treatment according to one aspect of the present invention has already been described, and therefore will not be described again here.

[0111] A pharmaceutical product for tumor therapy according to one embodiment of the present invention is used to treat tumors. The target tumor may be a multidrug-resistant tumor. The pharmaceutical product according to one embodiment of the present invention includes a package insert describing the dosage, administration method, etc. of the first tumor therapeutic agent or the second tumor therapeutic agent. The package insert preferably describes that when the first tumor therapeutic agent or the second tumor therapeutic agent is administered intravenously to human solid tumors, the amount of the S1P signaling inhibitor compound administered is preferably 2 to 5 mg, more preferably 3 mg or more, and even more preferably 4 mg or more per kg of body weight, and that these effective amounts can be administered in a single dose or in divided doses.

[0112] Furthermore, the first tumor therapeutic agent or the second tumor therapeutic agent in the pharmaceutical product for tumor treatment according to one aspect of the present invention may be contained in separate containers (vials, etc.) for each single dose, for example. The pharmaceutical product for tumor treatment according to one aspect of the present invention may include containers containing a single dose of the first tumor therapeutic agent or the second tumor therapeutic agent, for the number of doses required during the treatment period.

[0113] 5. Method for Treating Tumors A method for treating tumors using the first or second tumor therapeutic agent described above is also included in the scope of the present invention.

[0114] That is, one aspect of the present invention provides a method for treating a tumor as follows:

[21] A method for treating a tumor, comprising an administration step of administering the tumor therapeutic agent according to any one of [1] to

[10] or the multidrug-resistant tumor therapeutic agent according to

[21] to a recipient (e.g., a non-human mammal or a human).

[22] The method for treating a tumor according to

[21] , further comprising a selection step of selecting a patient having a tumor, wherein the recipient in the administration step is the patient selected in the selection step.

[23] The method for treating a tumor according to

[22] , wherein the selection step selects a patient having a multidrug-resistant tumor.

[24] The method for treating a tumor according to

[23] , wherein the multidrug-resistant tumor is breast cancer resistant to at least two anticancer drugs selected from the group consisting of eribulin, doxorubicin, and paclitaxel.

[0115] The first tumor therapeutic agent or the second tumor therapeutic agent in the tumor treatment method according to one aspect of the present invention has already been described, and therefore will not be described again here. Furthermore, the recipients, administration routes, formulations, and prescriptions of the first tumor therapeutic agent or the second tumor therapeutic agent are as described above in the section "1. Tumor therapeutic agents."

[0116] The selection step is a step of selecting patients with tumors. In the selection step, among patients with tumors, patients with multidrug-resistant tumors may be particularly selected. The method for selecting patients with tumors is not particularly limited, and, for example, patients with tumors can be selected by a method for selecting patients with tumor metastasis or recurrence. Furthermore, whether a tumor is a multidrug-resistant tumor can be confirmed by a method judging from the patient's chemotherapy treatment history and clinical course.

[0117] According to the tumor treatment method of one aspect of the present invention, a first tumor therapeutic agent or a second tumor therapeutic agent is administered to a subject (e.g., a non-human mammal or a human), thereby enabling treatment of a tumor in the subject (i.e., a patient). According to the tumor treatment method of one aspect of the present invention, even multidrug-resistant tumors that cannot be treated with conventional anticancer agents can be treated.

[0118] Furthermore, a complex having an S1P signaling inhibitory compound as a release site can react with acrolein present around tumor cells to release the S1P signaling inhibitory compound, making it suitable as a method for treating tumors.

[0119] <6. Others> Use of the conjugate according to one aspect of the present invention for producing a tumor therapeutic agent is also included in the scope of the present invention.

[0120] That is, one aspect of the present invention provides the following use:

[31] Use of a conjugate for the manufacture of a tumor therapeutic agent, the conjugate comprising an acrolein reactive site and a release site having a chemical structure represented by formula (1), the release site being bound to the acrolein reactive site via a linker that is cleavable by a reaction between the acrolein reactive site and acrolein, and the release site comprising the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that a hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * indicates a bonding site with the linker.)

[32] The use according to

[31] , wherein the linker has a chemical structure represented by formula (2). (In formula (2), R's each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (wherein a hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with the acrolein reaction site, and ** represents a bonding site with the detachment site.)

[33] The use according to

[32] , in which the ** in formula (2) represents a bonding site with a nitrogen atom, a sulfur atom, or an oxygen atom contained in the detachment site.

[34] The use according to

[32] , in formula (2), R's each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms (wherein a hydrogen atom constituting the alkyl group may have a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent).

[35] The use according to any one of

[31] to

[34] , wherein R1 and R2 in formula (1) each independently represent an alkyl group having 1 to 5 carbon atoms optionally substituted with at least one halogen atom.

[36] The use according to any one of

[31] to

[35] , wherein the conjugate reacts with acrolein present around tumor cells, thereby releasing the detachment site.

[37] The use according to any one of

[31] to

[36] , wherein the compound having activity of inhibiting sphingosine-1-phosphate signal transduction in the cells is a sphingosine-1-phosphate receptor modulator.

[38] The use according to

[37] , wherein the sphingosine-1-phosphate receptor modulator is fingolimod, siponimod, ozanimod, or ponesimod.

[39] The use according to any one of

[31] to

[38] , wherein the tumor is a multidrug-resistant tumor.

[40] The use according to

[39] , wherein the multidrug-resistant tumor is breast cancer resistant to at least two anticancer drugs selected from the group consisting of eribulin, doxorubicin, and paclitaxel.

[41] Use of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells for the manufacture of a therapeutic agent for multidrug-resistant tumors.

[0121] The conjugate for use in treating tumors is also included within the scope of the present invention.

[0122] The present invention is not limited to the above-described embodiments, and various modifications are possible within the scope of the claims. Embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention.

[0123] Chemical Synthesis: All chemically available reagents were used without further purification. Preparative separations were performed by column chromatography on Merck Silica Gel 60 (230-400 mesh). 1 H and 13 C NMR spectra were recorded using a JEOL RESONANCE AL400 NMR spectrometer. Unless otherwise noted, CDCl3 was used as the solvent. Chemical shifts are expressed as δ values ​​relative to the internal standard TMS. High-resolution mass spectrometry (HRMS) was recorded on a microTOF-QIII. Fluorescence spectra were measured using a spectrofluorometer (SpectraMax iD3, Molecular Devices). Because azide-containing compounds were expected to be explosive, all manipulations were performed carefully in a hood.

[0124] [Production Example 1] Synthesis of 4-azido-3,5-diisopropylbenzyl-(4-nitrophenyl)-carbonate (Compound 1) 4-azido-3,5-diisopropylbenzyl-(4-nitrophenyl)-carbonate (Compound 1) was synthesized according to the method described in Patent Document 1 (WO 2022 / 085523). The synthetic route of 4-azido-3,5-diisopropylbenzyl-(4-nitrophenyl)-carbonate (Compound 1) synthesized in Production Example 1 is as shown below. Each step is described in detail below.

[0125] (Production Example 1-1) Synthesis of 4-iodo-2,6-diisopropylaniline (Compound S1)

[0126] NaHCO 3 Saturated aqueous solution and Et2 To a solution (200 mL) of 2,6-diisopropylaniline (8.8 g, 44.9 mmol, 1.0 equiv.) in 1:1 O ([2,6-diisopropylaniline] = 0.2 M) was added iodine (13.7 g, 53.8 mmol, 1.2 equiv.). After stirring at room temperature for 5 h, Na 2 S 2 O 3 ・H 2 0 was added and the mixture was stirred for 15 min. The resulting mixture was diluted with Et 2 The combined organic phase was washed with brine and extracted with Na 2 SO 4 The filtrate was concentrated to dryness under reduced pressure to give the desired 4-iodo-2,6-diisopropylaniline (compound S1) as a red-black oil (13.4 g, 98% yield). 1 H NMR (400 MHz, CDCl3, 25 ℃) δ 7.27 (s, 2H), 3.70 (bs, 2H, NH2), 2.81 (hept, J = 6.7 Hz, 2H), 1.21 (d, J = 6.8 Hz, 12H); 13 C NMR (100 MHz, CDCl3, 25 ℃) δ140.27, 135.08, 131.79, 81.12, 27.82, 22.21; ESI-HRMS m / z C 12 H 19 IN ([M+H] + ) calculated value 304.0557, found value 304.0558.

[0127] (Production Example 1-2) Synthesis of ethyl 4-amino-3,5-diisopropylbenzoate (Compound S2)

[0128] 4-iodo-2,6-diisopropylaniline (compound S1) (6.2 g, 20.5 mmol, 1.0 equiv.) and Pd(PPh 3 ) 4 (0.5 g, 0.41 mmol, 0.02 equiv.) (17 mL, [S1] = 1.2 M) was added Et 3N (4.3 mL, 30.7 mmol, 1.5 equiv.) was added. The resulting solution was stirred at 110°C under CO pressure (0.5 MPa) for 8 hours. The suspension was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel using gradient elution [n-hexane / ethyl acetate (25:1 to 15:1)] to afford the desired ethyl 4-amino-3,5-diisopropylbenzoate (compound S2) as a yellow oil (4.4 g, 86% yield). 1 H NMR (400 MHz, CDCl3, 25 ℃) δ 7.75 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 4.16 (bs, 2H, NH2), 2.88 (hept, J = 6.9 Hz, 2H), 1.38 (t, J = 7. 2 Hz, 3H), 1.29 (d, J = 6.8 Hz, 12H); 13 C NMR (100 MHz, CDCl3, 25 ℃) δ 167.64, 145.10, 131.37, 125.04, 119.77, 60.30, 27.97, 22.24, 14.55; 15 H 24 NO2([M+H] + ) calculated value 250.1802, found value 250.1805.

[0129] (Production Example 1-3) Synthesis of 4-hydroxymethyl-2,6-diisopropylaniline (Compound S3)

[0130] To a 0°C solution of ethyl 4-amino-3,5-diisopropylbenzoate (compound S2) (764 mg, 3.1 mmol, 1.0 equiv.) in THF (30 mL, [S2] = 0.1 M) was slowly added DIBAL-H (9 mL of a 1.0 M solution in toluene, 9.2 mmol, 3.0 equiv.). The reaction was stirred under a nitrogen atmosphere at 0°C for 10 min and then at room temperature for 1 h. Excess DIBAL-H was carefully quenched with MeOH (20 mL) at 0°C, stirred for 30 min, and allowed to warm to room temperature. The resulting mixture was filtered through Celite (washing with MeOH), and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel using gradient elution [n-hexane / ethyl acetate (15:1 to 7:1)] to give the desired 4-hydroxymethyl-2,6-diisopropylaniline (compound S3) as an orange oil (627 mg, 99% yield). 1 H NMR (400 MHz, CDCl3, 25 ℃) δ 7.04 (s, 2H), 4.55 (s, 2H), 3.74 (bs, 2H, NH2), 2. 92 (hept, J = 6.7 Hz, 2H), 1.27 (d, J = 6.8 Hz, 12H); 13 C NMR (100 MHz, CDCl3, 25℃) δ 140.06, 132.71, 130.89, 122.46, 66.09, 27.99, 22.44; ESI-HRMS m / z C 13 H 22 NO2([M+H] + ) calculated value 208.1696, found value 208.1699.

[0131] (Production Example 1-4) Synthesis of (4-azido-3,5-diisopropylphenyl)-methanol (Compound S4)

[0132] To a mixture (35 mL, [S3] = 0.1 M) of 4-hydroxymethyl-2,6-diisopropylaniline (compound S3) (763 mg, 3.68 mmol, 1.0 equivalent) and sodium azide (610 mg, 9.20 mmol, 2.5 equivalent) dissolved in acetic acid and distilled water (5:2), sodium nitrite (628 mg, 8.83 mmol, 2.4 equivalent) was slowly added at 0°C. After stirring for 4 hours at 0°C, NaHCO 3 Saturated aqueous solution was added until the mixture reached pH 7. The mixture was extracted with EtOAc. The combined organic phases were washed with brine and 2 SO 4 The mixture was dried over ice and filtered. The filtrate was concentrated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel using gradient elution [n-hexane / ethyl acetate (30:1 to 15:1)] to afford the desired (4-azido-3,5-diisopropylphenyl)-methanol (compound S4) as a yellow oil (730 mg, 85% yield). 1 H NMR (400 MHz, CDCl3, 25 ℃) δ 7.13 (s, 2H), 4.64 (s, 2H), 3.36 (p, J = 6.8 Hz, 2H), 1.27 (d, J = 6.7 Hz, 12H); 13 C NMR (100 MHz, CDCl3, 25 ℃) δ143.51, 139.31, 134.84, 122.79, 65.27, 28.90, 23.52; ESI-HRMS m / z C 13 H 20 NO ([M+H] + ) calculated value 234.1601, detected value 234.1605.

[0133] (Production Example 1-5) Synthesis of 4-azido-3,5-diisopropylbenzyl-(4-nitrophenyl)-carbonate (Compound 1)

[0134] To a mixture of (4-azido-3,5-diisopropylphenyl)-methanol (compound S4) (297 mg, 1.27 mmol, 1.0 equiv.) and 4-nitrophenyl chloroformate (321 mg, 1.53 mmol, 1.2 equiv.) dissolved in THF (13 mL, [S4] = 0.1 M) at 0 °C, pyridine (206 mL, 2.55 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 24 hours. THF was removed by rotary evaporation, and the resulting crude product was purified by EtOAc-H 2 The combined organic phase was washed with brine and 2 SO 4 The mixture was dried over ice and filtered. The filtrate was concentrated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel (n-hexane / ethyl acetate 25:1) to give the desired 4-azido-3,5-diisopropylbenzyl-(4-nitrophenyl)-carbonate (Compound 1) as a yellow oil (424 mg, 84% yield). 1 H NMR (400 MHz, CDCl3, 25℃) δ 8.27 (d, J = 9.1 Hz, 2H), 7.20 (s, 2H), 5.26 (s, 2H), 3.38 (p, J = 6.9 Hz, 2H), 1.29 (d, J = 6.9 Hz, 12H); 13 C NMR (100 MHz, CDCl3, 25 ℃) δ 155.65, 152.50, 145.52, 143.82, 136.11, 132.62, 125.41, 124.63, 121.86, 71.07, 28.94, 23.53.

[0135] [Production Example 2] Synthesis of prodrug FTY720-ABC (compound 2) The synthetic route of FTY720-ABC (compound 2) synthesized in Production Example 2 is as shown below. FTY720 (drug name: fingolimod, compound name: 2-amino-2-[-2-(4-octylphenyl)ethyl]-1,3-propanediol) was obtained from Chayman Chemical Company.

[0136] To a mixture of compound 1 (100 mg, 0.25 mmol, 1.0 equiv.) and DIPEA (219 μL, 1.3 mmol, 5.5 equiv.) dissolved in DMF (2.5 mL, [1] = 0.1 M) was added FTY720 (95.0 mg, 0.28 mmol, 1.1 equiv.) at room temperature. The reaction mixture was stirred at room temperature for 20 hours. DMF was concentrated to dryness under reduced pressure. The resulting residue was purified by column chromatography on silica gel (CHCl 3 / MeOH(CHCl 3 Purification by HCl (up to 10:1) afforded the desired prodrug FTY720-ABC (compound 2) as a white solid (63.7 mg, 45%). 1 H NMR (400 MHz, CDCl3) δ 7.12 (s, 2H), 7.07 (d, J = 1.6 Hz, 4H), 5.30 (s, 1H), 5.04 (s, 2H), 3.92 (dd, J = 11.4, 6.1 Hz, 2H), 3.69 (dd, J = 11.6, 6.6 Hz, 2H), 3.35 (hept, J = 6.8 Hz, 2H), 3.12 (s, 2H), 2.62 - 2.49 (m, 4H), 1.94 - 1.86 (m, 2H), 1.36 - 1.18 (m, 22H), 0.91 - 0.83 (m, 3H).; 13 C NMR (101 MHz, CDCl3) δ 143.51, 140.77, 138.48, 135.34, 134.43, 128.55, 128.08, 124.00, 66.96, 66.63, 59.58, 35.53, 31.89, 31.57, 29.48, 29.34, 29.27, 29.04, 28.84, 23.46, 22.67, 14.11.; ESI-HRMS m / z C 33 H 50 N4NaO ([M+Na] + ) calculated value 589.3724, found value 589.3732.

[0137] Test Example 1: Preparation of a Breast Cancer Cell Line Resistant to Multiple Anticancer Drugs The MCF-7 breast cancer cell line, a human breast cancer cell line, was cultured over a long period of time in the presence of a low concentration of eribulin, and the surviving cells were cultured in gradually increasing concentrations of eribulin, thereby preparing an eribulin-resistant MCF-7 breast cancer cell line that was ultimately able to survive in the presence of a high concentration of eribulin (675 μM). It was confirmed that this cell line was resistant to multiple anticancer drugs due to cross-resistance.

[0138] Comparison of Growth Inhibitory Effects on Normal and Multidrug-Resistant Breast Cancer Cell Lines Example 1 Normal breast cancer cell line (MCF-7 breast cancer cell line) and multidrug-resistant cell line (Eribulin-resistant MCF-7 breast cancer cell line) were seeded into 96-well plastic plates at 2,000 cells / well with 90 μL / well of culture medium. The culture medium used was DMEM / F12 medium (containing phenol red) (Sigma, #D6434) supplemented with 10% FBS, 2.5 mM L-glutamine, and 6 ng / mL insulin.

[0139] Incubator at 37°C, CO 2 After culturing for 24 hours under the condition of 5%, 10 μL of medium containing FTY720 adjusted to a concentration 10 times the final test concentration was added to each well to make the total volume 100 μL / well. 2 After culturing for 48, 72, or 96 hours under 5% CO₂ conditions, the medium was removed from each well, and 90 μL of medium plus 10 μL of viable cell count reagent SF (Nacalai Tesque, #07553-44) was added per well, followed by culturing at 37°C for 2 hours.

[0140] The absorbance at 450 nm (reference wavelength: 650 nm) was measured using a SPECTRA max PLUS 384 (MOLECULAR DEVICES), and the cell viability at each concentration of FTY720 was calculated. 50 was calculated.

[0141] Example 2 The cell viability at each concentration of Prodrug-FTY-720 was calculated in the same manner as in Example 1, except that Prodrug-FTY-720 (Compound 1) synthesized in Production Example 1 was used instead of FTY720, and the IC 50 was calculated.

[0142] [Examples 3 to 5, Comparative Examples 1 to 3] The cell viability at each concentration of each drug in Examples 3 to 5 and Comparative Examples 1 to 3 was calculated in the same manner as in Example 1, except that the drugs shown in Table 1 were used instead of FTY720, and the IC 50 was calculated.

[0143]

[0144] (Results) The growth inhibitory effects of each of the drugs in Examples 1 to 5 and Comparative Examples 1 to 3 on normal breast cancer strains and multidrug-resistant breast cancer strains were compared. The results are shown in Figures 1 and 2. Figure 1 shows the results of comparing the growth inhibitory effects of each of the drugs in Comparative Examples 1 to 3 and Example 1 on normal breast cancer strains and multidrug-resistant breast cancer strains, and Figure 2 shows the results of comparing the growth inhibitory effects of each of the drugs in Examples 2 to 5 on normal breast cancer strains and multidrug-resistant breast cancer strains.

[0145] As shown in Figures 1 and 2, the S1P receptor modulators of Examples 1 and 3 to 5 were shown to have excellent growth inhibitory effects not only on normal breast cancer strains but also on multidrug-resistant breast cancer strains. This effect was also observed for the prodrug-FTY-720 (Compound 1) of Example 2. This demonstrates that S1P receptor modulators are effective against multidrug-resistant tumors.

[0146] [Test Example 2] <Preparation of an allogeneic orthotopic breast cancer mouse model> 4T1 cell line (5 × 10 5 The cells) were transplanted into the mammary gland of a BALB / c mouse (9 weeks old) together with 50 μL of a solution prepared by mixing BME (Cultrex Reduced Growth Factor Basement Membrane Extract) and cell culture medium (RPMI) at a 1:1 (volume ratio) to prepare an orthotopic breast cancer mouse model (hereinafter referred to as "breast cancer model mouse").

[0147] <Comparison of tumor weight and white blood cell and lymphocyte counts in blood samples> BALB / c mice that had not been transplanted with the 4T1 cell line or breast cancer model mice were divided into five groups, A to E, with 10 mice in each group. The mice in groups A to E were given the treatments shown in Table 2.

[0148]

[0149] FTY-720 or Prodrug-FTY-720 (Compound 1) was administered every three days, a total of three times. The dose of each drug was 240 nmol per mouse (FTY-720: 81.5 μg per mouse, Prodrug-FTY-720: 135.8 μg per mouse).

[0150] The mice were sacrificed on the day (1 day) or 3 days after the third administration, and blood and tumor samples were collected. For each group of mice, the weight and volume of the tumor were measured, and the white blood cell count and lymphocyte count were measured in the blood samples.

[0151] Tumor weight and volume were measured using the following method. Tumor weight was measured using a precision balance after tumor removal. Tumor volume was calculated using the following approximate formula: V = (W × L) / 2 (V: volume, W: minor axis, L: major axis). The percentage and number of lymphocytes in blood samples were measured by outsourced testing (Oriental Yeast Co., Ltd., automated method).

[0152] (Results) The results are shown in Figures 3 to 5. Figure 3 shows the results of comparing tumor weight, percentage of lymphocytes in blood samples, and lymphocyte count. In Figure 3, "Ct" represents the results for Group A, the control group, "FTY" represents the results for Group B, the FTY-720 administration group, and "Pro-FTY" represents the results for Group C, the Prodrug-FTY-720 administration group. In Figure 3, "LIM" means lymphocytes.

[0153] As shown in Figure 3, a decrease in tumor weight was observed in the FTY-720 administration group or the Prodrug-FTY-720 administration group compared to the control group. Furthermore, the decrease in lymphocytes in blood samples was significantly suppressed in the Prodrug-FTY-720 administration group compared to the FTY-720 administration group. These results demonstrate that by converting FTY-720 into a prodrug, tumor cells in tumor tissue can be regressed or reduced compared to before administration of the tumor therapeutic agent, and the immunosuppressive effect of FTY-720 can be attenuated. Although not shown in the figure, there was no decrease in the white blood cell count in blood samples in either the FTY-720 administration group or the Prodrug-FTY-720 administration group, and no difference was observed.

[0154] 4 is a graph showing the results of comparing the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in plasma in each group. In FIG. 4, "tumor-present FTY" represents the results for Group B, "tumor-present Pro-FTY" represents the results for Group C, and "tumor-free Pro-FTY" represents the results for Group D. Graph B is a graph showing the results of only the Prodrug-FTY-administered group shown in graph A, and graph C shows the time course of the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in plasma in Group C. In FIG. 4, FTY-720 is abbreviated as "FTY", phosphorylated FTY-720 as "FTY-P", and Prodrug-FTY-720 as "Prodrug-FTY".

[0155] As shown in Figure 4, most of the FTY-720 in the plasma of the FTY-720-administered group was phosphorylated. In contrast, in the Prodrug-FTY-720-administered group, the concentrations of converted FTY-720 and phosphorylated FTY-720 in the plasma were both below the detection limit. In the Prodrug-FTY-720-administered group, converted FTY-720 and phosphorylated FTY-720 were not detected in the plasma even 3 days after the third administration. Furthermore, 3 days after the third administration, the plasma concentration of Prodrug-FTY-720 had decreased to about one-third of that 1 day after the third administration.

[0156] 5 is a graph showing the results of comparing the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in tissues in each group. In FIG. 5, "tumor FTY" represents the results for Group B, "non-tumor FTY" represents the results for Group B, "tumor" represents the results for Group C, "tumor-containing normal" represents the results for Group C, and "tumor-free normal" represents the results for Group D. Graph B is a graph showing the results of only the Prodrug-FTY-administered group shown in graph A, and graph C shows the time course of the concentrations of FTY-720, phosphorylated FTY-720, or Prodrug-FTY-720 in tissues in Group C. In FIG. 5, FTY-720 is abbreviated as "FTY", phosphorylated FTY-720 as "FTY-P", and Prodrug-FTY-720 as "Prodrug-FTY".

[0157] As shown in Figure 5, high concentrations of FTY-720 accumulated in tissues in the FTY-720 administration group. The FTY-720 concentration in tissues was about 100 times that in plasma. In the Prodrug-FTY-720 administration group, converted FTY-720 and phosphorylated FTY-720 were observed to accumulate in tissues. The concentrations of converted FTY-720 and phosphorylated FTY-720 in tissues were similar to the concentrations of FTY-720 and phosphorylated FTY-720 in plasma in the FTY-720 administration group.

[0158] In the prodrug-FTY-720 group, converted FTY-720 and phosphorylated FTY-720 were detected in the normal tissue surrounding the tumor, but at lower concentrations than in the tumor area. Furthermore, converted FTY-720 and phosphorylated FTY-720 were still clearly detected in the tissues three days after the third administration. These results indicate that by converting FTY-720 into a prodrug, FTY-720 can be released slowly and reliably in the tumor.

[0159] Test Example 3 Comparison of Drug Sensitivity in Organoids Derived from Breast Cancer Patients Three types of organoids were used as organoids derived from breast cancer patients, as shown in Table 3. The organoids with sample name 11-T were organoids derived from a patient with multidrug-resistant breast cancer.

[0160]

[0161] (Assay Schedule) The assay was performed according to the method described in reference (Cell 172, 373-386, e1-e6, 2018). Specifically, each breast cancer patient-derived organoid was passaged as a single cell, and 5 days after passage, the cells were seeded into a 96-well plastic plate at approximately 1,000-2,000 cells / well with 80 μL / well of medium. The medium used was a cell culture medium (Type 1 or Type 2 medium containing growth factors added to Advanced DMEM / F12) supplemented with 100% BME2 at a volume of 10 μL per well.

[0162] Three to four days after seeding, medium containing a predetermined concentration of drug was added in an amount of 10 μL per well. The drugs used were Prodrug-FTY-720 (the drug of Example 2), eribulin (the drug of Comparative Example 1), doxorubicin (the drug of Comparative Example 2), and paclitaxel (the drug of Comparative Example 3).

[0163] Five days after the addition of the drug, a 3D Cell-Titer Glo assay was performed. For the 3D Cell-Titer Glo assay, an equal volume of GellTiter-Glo reagent to the medium was added to each well, and the mixture was stirred on a shaker. Luminescence was measured using a plate reader, and ATP, an indicator of metabolically active cells, was measured to determine the number of viable cells in the culture.

[0164] (Results) The results are shown in Figure 6. Figure 6 shows the results of comparing the growth inhibitory effects of the drugs of Comparative Examples 1 to 3 and Example 2 on organoids derived from breast cancer patients.

[0165] As shown in FIG. 6, it was found that by converting FTY-720 into a prodrug, it exhibited a strong growth-inhibitory effect even on organoids derived from patients with multidrug resistance to anticancer drugs.

[0166] The present invention can be used, for example, as a tumor treatment agent, and can be used in life science research, medical applications, and the like.

Claims

1. A tumor therapeutic agent comprising a complex having an acrolein reactive site and a detachment site, the detachment site having a chemical structure represented by formula (1), the detachment site being bonded to the acrolein reactive site via a linker that is cleavable upon reaction of the acrolein reactive site with acrolein, the detachment site comprising the chemical structure of a compound having activity of inhibiting sphingosine-1-phosphate signaling in cells. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with a linker.) 2. The tumor therapeutic agent according to claim 1, wherein the linker has a chemical structure represented by formula (2). (In formula (2), R each independently represents a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (wherein the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with the acrolein reaction site, and ** represents a bonding site with the separation site.) 3. The tumor therapeutic agent according to claim 2, wherein the ※※ in formula (2) is a bonding site with a nitrogen atom, a sulfur atom, or an oxygen atom contained in the detachment site.

4. The tumor therapeutic agent according to claim 2, wherein R in formula (2) is each independently a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms (wherein the hydrogen atom constituting the alkyl group may have a substituent selected from a halogen atom, a hydroxyl group, and an amino group which may have a substituent).

5. The tumor therapeutic agent according to claim 1, wherein R1 and R2 in formula (1) each independently represent an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom.

6. The tumor therapeutic agent according to claim 1, wherein the complex reacts with acrolein present around tumor cells, causing the detachment site to detach.

7. The tumor therapeutic agent according to claim 1, wherein the compound having activity of inhibiting sphingosine-1-phosphate signaling in the cells is a sphingosine-1-phosphate receptor modulator.

8. The tumor therapeutic agent according to claim 7, wherein the sphingosine-1-phosphate receptor modulator is fingolimod, siponimod, ozanimod, or ponesimod.

9. The tumor therapeutic agent according to claim 1, wherein the tumor is a multidrug resistant tumor.

10. The tumor therapeutic agent according to claim 9, wherein the multidrug resistant tumor is a breast cancer having resistance to at least two anticancer drugs selected from the group consisting of eribulin, doxorubicin and paclitaxel.

11. A therapeutic agent for multidrug resistant tumors, comprising as an active ingredient a compound having activity of inhibiting sphingosine-1-phosphate signal transduction in cells.

12. A complex comprising an acrolein reactive site having a chemical structure represented by formula (1) and a detachment site, wherein the detachment site is bonded to the acrolein reactive site via a linker that is cleavable upon reaction of the acrolein reactive site with acrolein, and the detachment site comprises the chemical structure of a sphingosine-1-phosphate receptor modulator. (In formula (1), R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms which may be substituted with at least one halogen atom, provided that at least one of R1 and R2 is an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group which may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms (provided that the hydrogen atom constituting the alkyl group may be substituted with a substituent selected from a halogen atom, a hydroxy group, and an amino group which may have a substituent); * represents a bonding site with a linker.) 13. The conjugate of claim 12, wherein the sphingosine-1-phosphate receptor modulator is fingolimod, siponimod, ozanimod, or ponesimod.

Citation Information

Patent Citations

  • Complex, and use thereof

    WO2022085523A1

  • Methods of treatment with s1p receptor modulators

    WO2022162088A2